SCHEMBL20116265

SCHEMBL20116265

CCOc1ccc(/C(N)=N/O)cc1OC

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.68
RECQL P46063 1/20 0.62
TSHR P16473 1/20 0.60
GAA P10253 2/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
PDE4A P27815 6/20 0.55
PDE4B Q07343 6/20 0.55
PDE4C Q08493 6/20 0.55
PDE4D Q08499 6/20 0.55
SMN1; SMN2 Q16637 1/20 0.54
KDM4E B2RXH2 1/20 0.53
MAPT P10636 1/20 0.53
PRSS1 P07477 3/20 0.51
HPGD P15428 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ALDH1A1 P00352 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29040322 1.00 MAPK1 (0.68) MAPK1RECQLTSHRGAAMEN1
SCHEMBL3181108 0.92 MAPK1 (0.55) MAPK1RECQLTSHRGAAMEN1
SCHEMBL3181095 0.92 MAPK1 (0.55) MAPK1RECQLTSHRGAAMEN1
SCHEMBL4221613 0.88 RECQL (0.77) RECQLTSHRGAAMEN1KMT2A
SCHEMBL30506314 0.88 RECQL (0.77) RECQLTSHRGAAMEN1KMT2A
SCHEMBL1660322 0.88 RECQL (0.77) RECQLTSHRGAAMEN1KMT2A
SCHEMBL30506235 0.81 RECQL (0.50) MAPK1RECQLTSHRGAAMEN1
SCHEMBL29040359 0.81 RECQL (0.50) MAPK1RECQLGAAMEN1KMT2A
SCHEMBL30506256 0.81 RECQL (0.50) MAPK1RECQLTSHRGAAMEN1
SCHEMBL20116382 0.81 RECQL (0.50) MAPK1RECQLTSHRGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 CN disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
CN-110099898-B Compounds and uses thereof 优曼尼蒂治疗公司 2023-07-25 CN disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 MAPK1 4304/4885RECQL 1132/4885TSHR 4679/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 MAPK1 4304/4885RECQL 1132/4885TSHR 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.